Genomes and Genes
neoplasm drug resistance
Summary: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Publications314 found, 100 shown here
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch
Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
N Engl J Med 350:2129-39. 2004..However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown...
- Tumour stem cells and drug resistanceMichael Dean
Laboratory of Genomic Diversity, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
Nat Rev Cancer 5:275-84. 2005..Gaining a better insight into the mechanisms of stem-cell resistance to chemotherapy might therefore lead to new therapeutic targets and better anticancer strategies...
- Multidrug resistance in cancer: role of ATP-dependent transportersMichael M Gottesman
Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Rev Cancer 2:48-58. 2002..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceZahid H Siddik
Department of Experimental Therapeutics, Unit 104, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Oncogene 22:7265-79. 2003..The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance...
- Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainWilliam Pao
Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
PLoS Med 2:e73. 2005..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance...
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCara A Rabik
Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 5841 S Maryland Avenue, Box MC2115, Section of Hem Onc, Chicago, IL 60637, United States
Cancer Treat Rev 33:9-23. 2007..Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclinical data that has clinical relevance generated over the past five years...
- Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastomaGentao Liu
Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA
Mol Cancer 5:67. 2006..The gene expression and the drug resistance property of CD133 positive cancer stem cells, however, are still unknown...
- Molecular determinants of resistance to antiandrogen therapyCharlie D Chen
Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
Nat Med 10:33-9. 2004..These findings provide insight toward the design of new antiandrogens...
- Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerRafael G Amado
Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
J Clin Oncol 26:1626-34. 2008..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
- Mechanisms of cancer drug resistanceMichael M Gottesman
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, Maryland 20892 4255, USA
Annu Rev Med 53:615-27. 2002..Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs...
- The resurgence of platinum-based cancer chemotherapyLloyd Kelland
Cancer Research Technology Development Laboratories, Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK
Nat Rev Cancer 7:573-84. 2007....
- A distinct "side population" of cells with high drug efflux capacity in human tumor cellsC Hirschmann-Jax
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, and DeBakey Department of Surgery, One Baylor Plaza, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 101:14228-33. 2004....
- Molecular mechanisms of drug resistanceD B Longley
Drug Resistance Laboratory, Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, N Ireland, UK
J Pathol 205:275-92. 2005..The ability to predict response to chemotherapy and to modulate this response with targeted therapies will permit selection of the best treatment for individual patients...
- Targeting multidrug resistance in cancerGergely Szakacs
Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Budapest Karolina út 29 H 1518 Hungary
Nat Rev Drug Discov 5:219-34. 2006..We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters...
- Ovarian cancer: strategies for overcoming resistance to chemotherapyRoshan Agarwal
Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK
Nat Rev Cancer 3:502-16. 2003..A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved...
- ERBB receptors and cancer: the complexity of targeted inhibitorsNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
Nat Rev Cancer 5:341-54. 2005..We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response...
- Apoptosis: a link between cancer genetics and chemotherapyRicky W Johnstone
Cancer Immunology Division, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, Smorgon Family Building, St Andrews Place, East Melbourne, 3002 Victoria, Australia
Cell 108:153-64. 2002....
- Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationM E Gorre
Department of Medicine, Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
Science 293:876-80. 2001..These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance...
- Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJiang Shou
The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 96:926-35. 2004..We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance...
- Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patientsRobert L Yauch
Department of Molecular Diagnostics, Genentech, Inc, South San Francisco, California 94080, USA
Clin Cancer Res 11:8686-98. 2005..These data support a potential role for EMT as a determinant of EGFR activity in NSCLC tumor cells and E-cadherin expression as a novel biomarker predicting clinical activity of the EGFR inhibitor erlotinib in NSCLC patients...
- Dynamics of chronic myeloid leukaemiaFranziska Michor
Program for Evolutionary Dynamics, Department of Organismic and Evolutionary Biology, Department of Mathematics, Harvard University, Cambridge, Massachusetts 02138, USA
Nature 435:1267-70. 2005..We calculate the probability of developing imatinib resistance mutations and estimate the time until detection of resistance. Our model provides the first quantitative insights into the in vivo kinetics of a human cancer...
- Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancerRita Nahta
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
Nat Clin Pract Oncol 3:269-80. 2006..Novel therapies targeted against these aberrant molecular pathways offer hope that the effectiveness and duration of response to trastuzumab can be greatly improved...
- Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugsChikashi Nakanishi
Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, 3 18 22, Honkomagome, Bunkyoku, Tokyo 113 8677, Japan
Nat Rev Cancer 5:297-309. 2005..What evidence is there that inhibitors of NF-kappaB might promote apoptosis in cancer cells and can NF-kappaB inhibitors be used to overcome resistance to chemotherapeutic agents?..
- A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerKatrien Berns
Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Cancer Cell 12:395-402. 2007..Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy...
- PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerFotios Loupakis
Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
J Clin Oncol 27:2622-9. 2009..This retrospective study investigated the role of PTEN loss, AKT phosphorylation, and KRAS mutations on the activity of cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC)...
- Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistanceR A Campbell
Department of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA
J Biol Chem 276:9817-24. 2001..Taken together, these results define a molecular link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERalpha, and inhibition of tamoxifen-induced apoptotic regression...
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsI F Tannock
Department of Medicine, Princess Margaret Hospital, Toronto, Canada
J Clin Oncol 14:1756-64. 1996..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
- A family of drug transporters: the multidrug resistance-associated proteinsP Borst
Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam
J Natl Cancer Inst 92:1295-302. 2000..The physiologic functions of the other MRPs are not known. Whether long-term inhibition of MRPs in humans can be tolerated (assuming that suitable inhibitors will be found) remains to be determined...
- Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)Y Lu
Department of Oncology, Jewish General Hospital, and McGill University, Montreal, PQ, Canada
J Natl Cancer Inst 93:1852-7. 2001..Thus, strategies that target IGF-IR signaling may prevent or delay development of resistance to trastuzumab...
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsYoichi Nagata
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Cell 6:117-27. 2004..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
- Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell linesAnthony D Yang
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
Clin Cancer Res 12:4147-53. 2006..In preliminary studies, we observed that oxaliplatin-resistant (OxR) colorectal cancer (CRC) cells underwent morphologic changes suggestive of a migratory phenotype, leading us to hypothesize that OxR CRC cells undergo EMT...
- Mechanisms of resistance to cisplatinM Kartalou
Division of Bioengineering and Environmental Health and Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Mutat Res 478:23-43. 2001..An improved understanding of the mechanisms of resistance operative in vivo has identified targets for intervention and may increase the utility of cisplatin for the treatment of cancer...
- HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsChristiane Knuefermann
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
Oncogene 22:3205-12. 2003....
- Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell deathAlexander Arlt
1Laboratory of Molecular Gastroenterology and Hepatology, 1st Department of Medicine, University of Kiel, Germany
Oncogene 22:3243-51. 2003....
- Development and characterization of gemcitabine-resistant pancreatic tumor cellsAmi N Shah
Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Ann Surg Oncol 14:3629-37. 2007..To study the mechanisms of chemoresistance in pancreatic cancer we developed two gemcitabine-resistant pancreatic cancer cell lines...
- Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancerFederica Di Nicolantonio
Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino, Medical School, Candiolo, Torino, Italy
J Clin Oncol 26:5705-12. 2008..Double-hit therapies aimed at simultaneous inhibition of epidermal growth factor receptor and BRAF warrant exploration in CRC patients carrying the V600E oncogenic mutation...
- Adaptive therapyRobert A Gatenby
Department of Integrative Mathematical Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA
Cancer Res 69:4894-903. 2009..e., when therapy-induced toxicity is absent). In vivo experiments using OVCAR xenografts treated with carboplatin show that adaptive therapy is feasible and, in this system, can produce long-term survival...
- Clinical relevance of MGMT in the treatment of cancerStanton L Gerson
Division of Hematology Oncology and Comprehensive Cancer Center, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH 44106 4937, USA
J Clin Oncol 20:2388-99. 2002..MGMT remains a paradigm for development of new agents that modulate known mechanisms of drug resistance in cancer cells and raise the spectra of combinatorial therapies that encompass known drug resistance mechanisms...
- Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 proteinRuud Oerlemans
Department of Rheumatology, VUMC Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
Blood 112:2489-99. 2008..Collectively, these findings establish a novel mechanism of bortezomib resistance associated with the selective overexpression of a mutant PSMB5 protein...
- Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cellsJanice M Knowlden
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, United Kingdom
Endocrinology 144:1032-44. 2003..These results demonstrate that TAM-R MCF-7 cell growth is mediated by the autocrine release and action of an EGFR-specific ligand inducing preferential EGFR/c-erbB2 dimerization and downstream activation of the ERK pathway...
- Rapamycins: mechanism of action and cellular resistanceShile Huang
Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
Cancer Biol Ther 2:222-32. 2003..Here we review the conserved TOR signaling pathways, conceptual basis for tumor selectivity, and the mechanisms of resistance to this class of antitumor agent...
- Apoptosis defects and chemotherapy resistance: molecular interaction maps and networksYves Pommier
Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, DHHS, Bethesda, MD 20892, USA
Oncogene 23:2934-49. 2004..They complement the p53, Chk2 and c-Abl maps published recently. We will also introduce the 'permissive apoptosis-resistance' model for the selection of multidrug-resistant cells...
- Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell linesSamir E Witta
Department of Medicine Medical Oncology, University of Colorado Health Sciences Center and University of Colorado Cancer Center, Campus Box 8117, PO Box 6511, Aurora, CO 80045, USA
Cancer Res 66:944-50. 2006..Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer...
- Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanomaClara Montagut
Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts, USA
Cancer Res 68:4853-61. 2008..Geldanamycin effectively promotes the degradation of CRAF, thereby revealing a potential therapeutic strategy to overcome resistance to RAF inhibition in a subset of BRAF mutant tumors...
- Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen
Cancer Center and Department of Pathology, Molecular Pathology Research Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
Proc Natl Acad Sci U S A 103:2316-21. 2006..MET amplification may thus identify a subset of epithelial cancers that are uniquely sensitive to disruption of this pathway and define a patient group that is appropriate for clinical trials of targeted therapy using MET inhibitors...
- Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copperKuniyuki Katano
Department of Medicine and the Cancer Center, University of California, San Diego, La Jolla, California 92093 0058, USA
Cancer Res 62:6559-65. 2002..These results are consistent with the concept that DDP enters and exits from the cell via transporters that normally mediate copper homeostasis...
- The role of glutathione-S-transferase in anti-cancer drug resistanceDanyelle M Townsend
Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Oncogene 22:7369-75. 2003..Some of the therapeutic strategies so far employed are described in this review...
- The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein researchMichael M Gottesman
Laboratory of Cell Biology, The Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
FEBS Lett 580:998-1009. 2006....
- Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cellsHiroaki Kajiyama
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
Int J Oncol 31:277-83. 2007..It is possible that therapeutic benefits such as the restoration of chemosensitivity or suppression of metastasis will be enabled by gaining further insight into the mechanisms underlying chemoresistance and EMT...
- Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancerLili Liu
State Key Laboratory of Cancer Biology, Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, 15 Changle West Road, Xi an 710032, China
Cancer Sci 99:121-8. 2008....
- Establishment of a human non-small cell lung cancer cell line resistant to gefitinibFumiaki Koizumi
Shien Lab, National Cancer Center Hospital, Tokyo, Japan
Int J Cancer 116:36-44. 2005..These phenotypes including EGFR-SOS complex and heterodimer formation of HER family members are potential biomarkers for predicting resistance to gefitinib...
- NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cellsMohamed Bentires-Alj
Center for Cellular and Molecular Therapy, University of Liege, Belgium
Oncogene 22:90-7. 2003..Moreover, NF-kappaB transactivates an mdr1 promoter luciferase construct. Our data thus demonstrate a role for NF-kappaB in the regulation of the mdr1 gene expression in cancer cells and in drug resistance...
- Activation of the PI3K/Akt pathway and chemotherapeutic resistanceKip A West
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Building 8, Room 5101, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA
Drug Resist Updat 5:234-48. 2002..Specifically inhibiting Akt activity may be a valid approach to treat cancer and increase the efficacy of chemotherapy...
- Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugsR Krishna
Department of Advanced Therapeutics, British Columbia Cancer Agency, BC V5Z 4E6, Vancouver, Canada
Eur J Pharm Sci 11:265-83. 2000....
- Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiationK A Robertson
Herman B. Wells Center for Pediatric Research, Department of Pediatrics, James Whircomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis 46202, USA
Cancer Res 61:2220-5. 2001..To our knowledge, this is the first example of overexpressing Ape1/ref-1 in a mammalian system resulting in enhanced protection to DNA-damaging agents...
- An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell linesJennifer D Davidson
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
Cancer Res 64:3761-6. 2004..The results from this study indicate that the level of RRM1 may affect gemcitabine response. Furthermore, RRM1 may serve as a biomarker for gemcitabine response...
- Nucleoside analogues: mechanisms of drug resistance and reversal strategiesC M Galmarini
, Laboratoire de Cytologie Analytique, , Lyon, France
Leukemia 15:875-90. 2001..Strategies aiming to increase the intracellular concentrations of active compounds are presented...
- Mechanisms of Taxol resistance related to microtubulesGeorge A Orr
Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Oncogene 22:7280-95. 2003..A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context...
- The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxelAhmed Ashour Ahmed
Functional Genomics of Drug Resistance Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
Cancer Cell 12:514-27. 2007..These data show that ECM can mediate taxane sensitivity by modulating microtubule stability...
- Multicellular resistance: a paradigm for clinical resistance?B Desoize
Laboratoire de Biochimie et de Biologie Moleculaire, Faculte de Pharmacie, IFR 51, EA 2063, Reims, France
Crit Rev Oncol Hematol 36:193-207. 2000..The explanation given is that it improves drug penetration into spheroids. We now hypothesise that hyaluronidase, in fact, decreases MCR and thus could be the first member of a new therapeutic class...
- Chemotherapy resistance in osteosarcoma: current challenges and future directionsAlexander J Chou
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Expert Rev Anticancer Ther 6:1075-85. 2006..In this review, the focus is on the current understanding of the mechanisms of resistance to the most commonly used agents in the treatment of osteosarcoma and the methods employed to overcome chemotherapy resistance...
- Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cellsDavid L Shattuck
University of California Davis Cancer Center, Sacramento, CA 95817, USA
Cancer Res 68:1471-7. 2008..Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met...
- Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosisLavinia Nardinocchi
Department of Experimental Oncology, Molecular Oncogenesis Laboratory, Regina Elena Cancer Institute, 00158 Rome, Italy
Mol Cancer 8:1. 2009....
- Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathwayXiaokui Yang
Reproductive Biology Unit and Division of Gynaecology Oncology, Department of Obstetrics and Gynaecology and Cellular and Molecular Medicine, University of Ottawa, Ontario, Canada
Cancer Res 66:3126-36. 2006..Understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer...
- Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinibTakayuki Kosaka
Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Clin Cancer Res 12:5764-9. 2006..Part of this "acquired resistance" is attributable to a secondary mutation resulting in threonine to methionine at codon 790 (T790M) of EGFR...
- Biochemical, cellular, and pharmacological aspects of the multidrug transporterS V Ambudkar
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Annu Rev Pharmacol Toxicol 39:361-98. 1999..This review summarizes current research on the structure-function analysis of P-glycoprotein, its mechanism of action, and facts and speculations about its normal physiological role...
- Ceramide glycosylation potentiates cellular multidrug resistanceY Y Liu
John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA 90404, USA
FASEB J 15:719-30. 2001..This study reveals that GCS is a novel mechanism of multidrug resistance and positions GCS antisense as an innovative force to overcome multidrug resistance in cancer chemotherapy...
- The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsT Hideshima
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 61:3071-6. 2001..Given the acceptable animal and human toxicity profile of PS-341, these studies provide the framework for clinical evaluation of PS-341 to improve outcome for patients with this universally fatal hematological malignancy...
- A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patientElena Tamborini
Department of Pathology, Istituto Nazionale per lo Studio e al Cura dei Tumori, Milan, Italy
Gastroenterology 127:294-9. 2004..Molecular mechanisms have been reported in CML and GIST for primary resistance, whereas extensive studies on the mechanisms responsible for secondary resistance have been almost exclusively reported for CML...
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJeffrey A Engelman
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
J Clin Invest 116:2695-706. 2006....
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerHelena Linardou
1st Department of Medical Oncology, Metropolitan Hospital, Athens, Greece
Lancet Oncol 9:962-72. 2008..The aim of this systematic review and meta-analysis was to assess if k-RAS mutations represent a candidate predictive biomarker for anti-EGFR-targeted therapeutic strategies in mCRC and NSCLC...
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaNeil P Shah
Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Cancer Cell 2:117-25. 2002..Multiple independent mutant clones were detected in a subset of relapsed cases. Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance...
- Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemiaTakuya Matsunaga
Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, South 1, West 16, Chuo Ku, Sapporo 060 0061, Japan
Nat Med 9:1158-65. 2003..4% for 15 VLA-4-positive patients. Thus, the interaction between VLA-4 on leukemic cells and fibronectin on stromal cells may be crucial in bone marrow MRD and AML prognosis...
- Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasMoshe Talpaz
Department of Leukemia, M D Anderson Cancer Center, Houston, USA
N Engl J Med 354:2531-41. 2006..We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemia (CML) or Ph-positive acute lymphoblastic leukemia (ALL)...
- Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpressionFrancois Xavier Mahon
Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U876, Universite Victor Segalen, Laboratoire d hématologie CHU de Bordeaux, Bordeaux Cedex, France
Cancer Res 68:9809-16. 2008..Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance...
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
N Engl J Med 351:1502-12. 2004..We compared such treatment with docetaxel plus prednisone in men with this disease...
- Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkChristoph A Ritter
Institute of Pharmacology, University of Greifswald, Greifswald, Germany
Clin Cancer Res 13:4909-19. 2007..We have investigated mechanisms of acquired resistance to the HER2 antibody trastuzumab in BT-474 human breast cancer cells...
- Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumorsToshiyasu Taniguchi
Department of Pediatric Oncology, Dana Farber Cancer Institute, Guy s King s and St Thomas School of Medicine, London, UK
Nat Med 9:568-74. 2003..We propose a model for ovarian tumor progression in which the initial methylation of FANCF is followed by FANCF demethylation and ultimately results in cisplatin resistance...
- Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2Suniti Misra
Department of Cell Biology and Anatomy, Medical University of South Carolina, Charleston, South Carolina 29425, USA
J Biol Chem 280:20310-5. 2005..This pathway may also be important in progression of other malignant characteristics. These results illustrate the potential importance of hyaluronan as a therapeutic target in multidrug-resistant carcinomas...
- Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathwayByeong Hyeok Choi
Department of Biomedical Science and Technology, IBST, Konkuk University, Seoul 143 701, Republic of Korea
Cancer Lett 259:111-8. 2008..Thus, curcumin can contribute to the reversal of the MDR phenotype, probably due to the suppression of P-gp expression via the inhibition of the PI3K/Akt/NF-kappa B signaling pathway...
- Overriding imatinib resistance with a novel ABL kinase inhibitorNeil P Shah
Division of Hematology and Oncology, Department of Medicine, The David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA
Science 305:399-401. 2004..These data illustrate how molecular insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies...
- Proteasome inhibitors in cancer therapy: lessons from the first decadeRobert Z Orlowski
Department of Lymphoma Myeloma, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:1649-57. 2008..This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside...
- Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cellsAmy S Clark
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
Mol Cancer Ther 1:707-17. 2002....
- p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cellsMichael Fraser
Reproductive Biology Unit and Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, University of Ottawa, Ottawa Health Research Institute, 725 Parkdale Avenue, Ottawa, Ontario KIY 4E9, Canada
Cancer Res 63:7081-8. 2003..Inhibition of Xiap and/or Akt expression/function may be an effective means of overcoming chemoresistance in ovarian cancer cells expressing either endogenous or reconstituted wild-type p53...
- Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticJunya Kuroda
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
Proc Natl Acad Sci U S A 103:14907-12. 2006..These results demonstrate that Bim and Bad account for most, perhaps all, imatinib-induced killing of Bcr/Abl+ leukemic cells and suggest previously undescribed drug combination strategies for cancer therapy...
- NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenograftsKaruppaiyah Selvendiran
Davis Heart and Lung Research Institute and Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
Cell Cycle 7:81-8. 2008..Thus, NCX-4016 appears to be a potential therapeutic agent for treating recurrent human ovarian carcinoma...
- Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progressionJean Philippe Cosse
Laboratory of Biochemistry and Cellular Biology, FUNDP University of Namur, 5000 Namur, Belgium
Anticancer Agents Med Chem 8:790-7. 2008..The aim of this review is to provide a description of known hypoxia-induced mechanisms of chemoresistance at a cellular level...
- Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancerUrsula B McGovern
Cancer Research UK Labs, Department of Oncology, Imperial College London, MRC Cyclotron Building, Imperial College School of Medicine at Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
Mol Cancer Ther 8:582-91. 2009..In summary, our study defined FOXM1 as a cellular target and marker of gefitinib activity in breast cancer...
- Overcoming drug resistance by enhancing apoptosis of tumor cellsPepita Gimenez-Bonafe
Departament de Ciències Fisiològiques II, Campus Ciènces de Salut de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain
Curr Cancer Drug Targets 9:320-40. 2009....
- The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugsKatherine Wu
Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095 736422, USA
Crit Rev Immunol 29:241-54. 2009..Thus, pharmacological agents regulating the RKIP-NF-kappaB-Snail loop can be used as both sensitizing agents for apoptosis when combined with cytotoxic therapies as well as inhibitors of metastasis...
- Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncologyUltan McDermott
Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA
J Clin Oncol 27:5650-9. 2009..In this review, we summarize recent developments in this area, and we highlight some of the logistical challenges posed by this emerging paradigm in medical oncology...
- Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistanceTianhua Guo
Departments of Pathology, Medicine, and Surgery, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
Clin Cancer Res 15:6862-70. 2009..The clinical benefit of sunitinib is genotype-dependent in regards to both primary and secondary mutations, with GIST patients harboring the KIT(AY502-3ins) exon 9 mutation being the most sensitive...
- Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapyTing Ting Tan
Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey 08854, USA
Cancer Cell 7:227-38. 2005....
- Drug resistance and the solid tumor microenvironmentOlivier Tredan
Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
J Natl Cancer Inst 99:1441-54. 2007....
- Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patientsG Ferrandina
Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
Ann Oncol 13:1205-11. 2002..The aim of this study was to investigate the expression of COX-2 and its association with clinicopathological parameters, response to treatment, and clinical outcome in ovarian cancer patients...
- A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumorsLei L Chen
Department of Sarcoma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA llchen mdanderson org
Cancer Res 64:5913-9. 2004..Allelic-specific sequencing data show that this new mutation occurs in the allele that harbors original activation mutation of KIT...
- Angiogenesis in life, disease and medicinePeter Carmeliet
Center of Transgene Technology and Gene Therapy, University of Leuven, Flanders Interuniversity Institute for Biotechnology VIB, B 3000 Leuven, Belgium
Nature 438:932-6. 2005..Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments...
- Signalling via integrins: implications for cell survival and anticancer strategiesStephanie Hehlgans
OncoRay, Center for Radiation Research in Oncology, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Fetscherstrasse 74 PF 86, 01307 Dresden, Germany
Biochim Biophys Acta 1775:163-80. 2007....
- Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358Michele Modugno
Nerviano Medical Sciences Srl Oncology, Milan, Italy
Cancer Res 67:7987-90. 2007....
- Platinum resistance: the role of DNA repair pathwaysLainie P Martin
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 14:1291-5. 2008....
- Mcl-1: a gateway to TRAIL sensitizationSeok Hyun Kim
Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine, Institute for Translational Medicine and Therapeutics, Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Cancer Res 68:2062-4. 2008..Using the TRAIL-sorafenib combination as a tactic to more effectively kill cancer cells may provide an effective tool to attack a variety of human cancers that are largely presently untreatable...
- Monoclonal Antibody Therapy for Follicular LymphomaJonathan Friedberg; Fiscal Year: 2007..abstract_text> ..
- Defibrotide for the treatment of severe hepatic veno-cc*Paul Richardson; Fiscal Year: 2007..Abstract Not Provided ..
- Inhibition of Tumor Progression by Hyaluronan OligomersBryan Toole; Fiscal Year: 2008..unreadable] [unreadable]..
- PERTURBATION OF HYALURONAN FUNCTION IN CANCERBryan P Toole; Fiscal Year: 2010..Consequently, these approaches will help to guide further development of therapeutic interventions in cancer patients, employing antagonists of deregulated HA interactions. ..
- TUMOR CELL STROMAL INTERACTIONS IN CANCERBryan Toole; Fiscal Year: 2004..Interference with EMMPRIN action may then be an effective way to inhibit tumor progression patients. ..
- Proapoptotic Therapy for B-cell Non Hodgkin's LymphomaAjay Gopal; Fiscal Year: 2007..unreadable] [unreadable]..
- Antioxidant Strategies for Parkinson's DiseaseNina Schor; Fiscal Year: 2005..abstract_text> ..
- TARGETED THERAPY FOR CHEMORESISTANT TUMORSNina Schor; Fiscal Year: 2006..Ultimately, this predictive panel will help to identify those patients whose chemoresistant tumors are likely to be particularly sensitive to enediyne treatment. [unreadable] [unreadable]..
- OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMAAjay Gopal; Fiscal Year: 2005..We anticipate that these interventions will ultimately enhance the prognosis for patients with relapsed lymphoma by increasing the response and survival rates, while simultaneously minimizing toxicities. ..
- Changes in Tumor DNA Methylation with DecitabineDavid Stewart; Fiscal Year: 2006..This preliminary look at individual genes may provide a molecular rationale for future decitabine therapeutic studies in specific relevant tumor types. ..
- Targeting Akt/NF-kappa beta for Pancreatic Cancer TherapyFazlul Sarkar; Fiscal Year: 2007..These results will provide mechanistic as well as pre-clinical data in support of our hypotheses and may open new and novel avenues for the treatment of human pancreatic cancer. ..
- Biology of Imatinib-Resistant Mutants of BCR-ABLMichael Deininger; Fiscal Year: 2009..Such crucial proteins may then be exploited as drug targets for the treatment of chronic myeloid leukemia, and further, for other types of cancer. ..
- BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' LymphomaStephen Ansell; Fiscal Year: 2008..abstract_text> ..
- Therapeutic Modulation of COX-2-induced Immunosuppression in Metastatic RCCBrian Rini; Fiscal Year: 2008..This project will have broad implications for the immunoregulation of cancer and how expression and modulation of COX-2 expression influences the immune response to cancer. [unreadable] [unreadable] [unreadable]..
- NEUROTROPHIC MECHANISMS IN NEUROBLASTOMANina Schor; Fiscal Year: 2008..abstract_text> ..
- CD44/VARIANT CYTOSKELETON IN BREAST CANCER PROGRESSIONLILLY YW BOURGUIGNON; Fiscal Year: 2010....
- CD44-P185HER2 INTERACTION IN OVARIAN CANCER PROGRESSIONLILLY BOURGUIGNON; Fiscal Year: 2007..abstract_text> ..
- NEURODEVELOPMENTAL AND NEURODEGERENTATIVE DISEASENina Schor; Fiscal Year: 2005..Funding of this program will perpetuate this history at an economically and academically critical time. ..
- Phase I Clinical Trials of Anti-Cancer AgentsFrancis Giles; Fiscal Year: 2007..abstract_text> ..
- A Novel Vitamin D Target in Human Prostate CancerTOMASZ BEER; Fiscal Year: 2007..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..
- MECHANISMS OF TRANSFORMATION OF HEMATOPOIETIC CELLSJAMES MC CUBREY; Fiscal Year: 2001..An understanding of how these signal transduction and apoptotic pathways impinge upon one another will further our comprehension of the consequences of abnormal oncogene activation and tumor progression. ..
- Epigenetic Chromatin Changes as Melanoma MarkersRuth Halaban; Fiscal Year: 2006..Altogether, the results are likely to generate a novel marker(s) that can be used to assess propensity for malignant transformation, tumor progression and/or sensitivity to chemotherapeutic drugs that target chromatin conformation. ..
- CANCER AND LEUKEMIA GROUP BMartin Edelman; Fiscal Year: 2002..The grant will also allow for continuation of meritorious pilot protocols and will allow GCC to monitor and collect data which will produce mutual benefit to the GCC and CALGB. ..
- EPR IMAGING OF TUMOR HETEROGENEITY AND OXYGENATIONPeriannan Kuppusamy; Fiscal Year: 2003..Information obtained from these studies should enable the development and optimization of therapeutic modalities for cancer treatment. ..
- Antitumor Antimitotics That Reverse Tumor ResistanceAleem Gangjee; Fiscal Year: 2010..The study will also further define the mechanism of action of the novel series and could afford agents for clinical use. ..
- Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitorsRoberto Pili; Fiscal Year: 2010....
- ROLE OF THE CELL CYCLE IN HYPERSENSITIVITY TO ESTRADIOLRichard Santen; Fiscal Year: 2008..A clinical trial in women, which is designed to specifically demonstrate that high dose estrogen induces tumor regression through the mechanism of apoptosis will be conducted. ..
- DELTAVISION RESTORATION MICROSCOPY SYSTEM MODEL 483Conly Rieder; Fiscal Year: 2001..This Core will maintain the instrument and provide technical support to those Principal Investigators/Program Directors who are in need of low-light high- resolution 3-D fluorescent imaging. ..
- Perivascular Invasion of GBMsGabriele Bergers; Fiscal Year: 2010..AIM2.1: Identify the exact cell sources of MMP-9 production in GBM. AIM2.2: Reveal function of host cell-produced MMP-9 in angiogenesis and invasion. AIM2.3: Elicit function of tumor cell-produced MMP-9 in angiogenesis and invasion. ..
- Role of BMDCs in Solid Tumor Growth and RelapseRakesh K Jain; Fiscal Year: 2010..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
- THERAPEUTICS STUDIES OF PRIMARY CNS MALIGNANCIESPatrick Wen; Fiscal Year: 2008..abstract_text> ..
- Structural biology of kinase signaling in T-cellsMichael J Eck; Fiscal Year: 2010..Also, they will help us to understand the causes of immune deficiency diseases XLP and SCID at a detailed molecular level. ..
- Amnis ImageStream Flow CytometerCraig Jordan; Fiscal Year: 2007..Taken together, the unique capabilities of the ImageStream system will therefore serve to strongly benefit a wide range of research activities. [unreadable] [unreadable] [unreadable]..
- Role of Fra-1 in MesotheliomaMaria Ramos Nino; Fiscal Year: 2008..The long-term goal of this research plan is to understand the molecular mechanisms governing mesothelial cell tumorigenesis. ..
- Integrative Biology of Tumor MetastasisRakesh Jain; Fiscal Year: 2009..Finally, we have the resources and the clinical collaborators in place to initiate a clinical trial based on our findings, as attested by our ongoing trial using a VEGF-specific antibody. ..
- Resistance and Response Mechanisms to Prostate Cancer TherapyTOMASZ BEER; Fiscal Year: 2009..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
- TARGET-GUIDED DEVELOPMENT OF SPECIFIC AKT INHIBITORSPeter Vogt; Fiscal Year: 2008..4) Investigate the structure-activity relationship through in situ click chemistry and optimize inhibitors for potency, selectivity and cell-based activity ..
- Early prediction of response to combined modality therapy by functional imagingJann Sarkaria; Fiscal Year: 2008..If successful, this approach would facilitate the selection of the most efficacious therapies for individual patients. [unreadable] [unreadable] [unreadable]..
- Controlling the Max NetworkPeter Vogt; Fiscal Year: 2008..The proposed work on stabilizers in the Myc-Max network could open the door to a new way of influencing and directing cell growth. ..
- Oregon Prostate Cancer Conference 2001TOMASZ BEER; Fiscal Year: 2003....
- REGULATION OF MDR GENE EXPRESSION IN LIVER CANCERSMACUS KUO; Fiscal Year: 2004..We hope from this research, which includes in vitro cell culture and in vivo animal and tumor models, to gain important molecular insights into the genetic resolution of drug resistance and hepatocarcinogenesis. ..
- Biomodulation of capecitabine by docetaxel in non-small*MIGUEL VILLALONA; Fiscal Year: 2005..Confirmation of our working hypothesis may lead to a new treatment paradigm suitable for evaluation in the adjuvant setting. ..
- CONFERENCE/WORKSHOP ON EPR SPECTROSCOPY AND IMAGINGPeriannan Kuppusamy; Fiscal Year: 2005..S. members of the International Advisory Committee for this meeting. Particular emphasis will be given to the minority and women scientists, encouraging their active participation. ..
- PROLIFERATION & MALIGNANT TRANSFORMATION OF MELANOCYTESRuth Halaban; Fiscal Year: 2004..Our functional studies may provide a basis for the design of new therapeutical agents for the treatment of patients with metastatic melanomas. ..
- LIPOSOMAL BCL-2 ANTISENSE THERAPY FOR SOLID TUMORSFrancisco Esteva; Fiscal Year: 2003..Gabriel Lopez-Berestein (Department of Bioimmunotherapy). M. D. Anderson Cancer Center has the patients and resources necessary for Dr. Esteva to successfully complete this research project. ..
- Interdisciplinary Study of Acid-Meditated Tumor InvasionRobert Gatenby; Fiscal Year: 2005..Perturbations that produce slowing or reversal of the traveling wave solution to the state equations (ie tumor growth) will be explored to predict possible new treatment strategies. ..
- NEW SYNTHESIS OF BIOCHEMICALS WITH HOMOGENEOUS CATALYSTSIwao Ojima; Fiscal Year: 2003..In this project, we plan to develop new synthetic routes to a variety of enantiopure heterocyclic and carbocyclic compounds of medicinal interest featuring diastereoselective or enantioselective catalytic processes as the key steps. ..
- Conference on Angiogenesis in Cancer and Other DiseasesRakesh Jain; Fiscal Year: 2002..The meeting's synthesis of available information will be particularly thought-provoking for students and post- doctoral fellows. ..
- Anti-Angiogenesis/Drugs in Tumors--Bench /Bedside & BackRakesh Jain; Fiscal Year: 2005..Attendance at this conference will provide an excellent opportunity for young investigators working on cancer to educate and familiarize themselves with the field of angiogenesis and the complexities of the system. ..
- REGULATION OF GENES BY T AND DHT IN RAT AND HUMAN PROSTAMichael McPhaul; Fiscal Year: 2001..The results of these studies will help define the distinct roles that T and DHT play in androgen physiology and indicate the directions that efforts to selectively interfere with the actions of T and DHT can take. ..
- CALCITRIOL & DEXAMETHASONE FOR MYELODYSPLASTIC SYNDROMESROBERT REDNER; Fiscal Year: 2004..Abstract Not Provided ..
- Novel Cationic 99mTc Complexes for Heart ImagingShuang Liu; Fiscal Year: 2006..Successful development of new 99mTc perfusion imaging agents will have a profound impact on diagnostic evaluation, risk stratification, and therapeutic decision-making in patients with CAD. ..
- In Vivo EPR Imaging of Redox Status and Thiols in TumorPeriannan Kuppusamy; Fiscal Year: 2007..The results will enable a better understanding of the development of drug resistance in ovarian cancer and offer efficient diagnosis for effective treatment of ovarian cancer patients. ..
- Novel Single, Dual and Multitargeted Inhibitors of RTKsAleem Gangjee; Fiscal Year: 2007..abstract_text> ..
- Single Agents with Designed Combination Chemotherapy PotentialAleem Gangjee; Fiscal Year: 2010..abstract_text> ..
- NOVEL NONINDUCIBLE THYMIDYLATE SYNTHASE INHIBITORSAleem Gangjee; Fiscal Year: 2004....
- FUNCTIONAL ANALYSIS OF THE PTEN TUMOR SUPPRESSOR PROTEINLevi Garraway; Fiscal Year: 2009..Based on this data we propose in specific aims 2 and 3: 2. To generate antibody reagents that selectively recognizes unphosphorylated PTEN. 3. To purify and identify proteins in the PTEN associated complex (PAC). ..
- Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor AgentsAleem Gangjee; Fiscal Year: 2010....
- Novel, P. jirovecii Specific Antipneumocystis AgentsAleem Gangjee; Fiscal Year: 2009..These agents could be used alone or in combination to treat PCP thus providing novel agents against a new target. ..
- Combination Strategies for Angiogenesis InhibitionKeith Flaherty; Fiscal Year: 2008..He is a recognized leader in the field of investigational therapies, has a record of mentoring successful clinical researchers, and is committed to Dr. Flaherty's training. ..
- Reversal of 5-FU Resistance by Arsenic Trioxide in Colorectal CarcinomaBach Ardalan; Fiscal Year: 2008..Aim 2: Determine if ATO administration down regulates the expression of thymidylate synthase in tumor and in PBMC in patients receiving ATO + 5-FU. [unreadable] [unreadable] [unreadable]..
- Implications of Retinoid-Induced CD38 Antigen ExpressionKapil Mehta; Fiscal Year: 2006..unreadable] [unreadable]..
- AIDS MALIGNANCY CONSORTIUMJoseph Sparano; Fiscal Year: 2005..abstract_text> ..
- Effect of HIV-1 Vpr on Basic Cellular Functions (II)Richard Zhao; Fiscal Year: 2007..abstract_text> ..
- Bleomycin Hydrolase and Alzheimer's DiseaseJOHN LAZO; Fiscal Year: 2004..These studies should provide new mechanistic information concerning the pathogenesis of AD as well as reagents for future therapeutic studies. ..
- A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to ErVincent Miller; Fiscal Year: 2008..The proposed work is a clinical trial to determine whether dasatinib is an effective treatment for patients with NSCLC and acquired resistance to erlotinib or gefitinib. [unreadable] [unreadable] [unreadable]..
- Chemical Complementation Assay for MKP-3 (RMI)JOHN LAZO; Fiscal Year: 2005..This proposal will provide sufficient reagents, including cells and DMA transfection vectors, to permit the high throughput screening of 100,000 compounds. ..
- In Vitro High Throughput Screening Assay for MKP-3(RMI)JOHN LAZO; Fiscal Year: 2005..Nonetheless, no potent or selective small molecule inhibitors of this protein phosphatase have been identified. This proposal will provide sufficient reagents to permit a high throughput screening of 100,000 compounds ..
- FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCEMignon Loh; Fiscal Year: 2003..abstract_text> ..
- Chemical Complementation Assay for MKP-1 (RMI)JOHN LAZO; Fiscal Year: 2005..This proposal will provide sufficient reagents, including cells and DMA transfection vectors, to permit the high throughput screening of 100,000 compounds. ..
- BIOCHEMICAL REGULATORS OF BLEOMYCIN INDUCED TUMORSJOHN LAZO; Fiscal Year: 2001..The Specific Aims are to: 1) develop cells and mice deficient in BH, 2) develop cells and mice that overexpress BH, 3) isolate and characterize potential proteins that interact with BH and, 4) analyze the regulation of BH expression. ..
- ACOUSTICALLY ACTIVATED MICELLAR DRUG DELIVERYNatalya Rapoport; Fiscal Year: 2001....